Literature DB >> 34511372

Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.

Robin A Pollini, Susannah Slocum, Jenny Ozga, Rebecca Joyce, Ziming Xuan, Traci C Green, Alexander Y Walley.   

Abstract

OBJECTIVES: In a prior statewide naloxone purchase trial conducted in Massachusetts, we documented a high rate of naloxone dispensing under the state's standing order program. The purpose of this study was to understand the factors that facilitate naloxone access under the Massachusetts naloxone standing order (NSO) program and identify any remaining barriers amenable to intervention.
DESIGN: Mixed methods design involving a pharmacist survey and 3 pharmacist focus groups. SETTING AND PARTICIPANTS: Focus groups were conducted at 3 separate professional conferences for pharmacists (n = 27). The survey was conducted among Massachusetts pharmacists (n = 339) working at a stratified random sample chain and independent retail pharmacies across Massachusetts. All data were collected between September 2018 and November 2019. OUTCOME MEASURES: Facilitators and barriers to NSO implementation and naloxone dispensing and pharmacists' attitudes and beliefs regarding naloxone and opioid use.
RESULTS: Most pharmacists described NSO implementation as being straightforward, although differences were reported by pharmacy type in both the survey and focus groups. Facilitators included centralized implementation at chain pharmacies, access to Web-based resources, regularly stocking naloxone, and use of naloxone-specific intake forms. Barriers included patient confidentiality concerns and payment/cost issues. Only 31% of surveyed pharmacists reported always providing naloxone counseling; the most commonly cited barriers were perceived patient discomfort (21%) and time limitations (14%). Confidential space was also more of a concern for independent (vs. chain) pharmacists (18% vs. 6%, P = 0.008). A majority of pharmacists held supportive attitudes toward naloxone, although some reported having moral/ethical concerns about naloxone provision.
CONCLUSION: We documented several facilitators to NSO implementation and naloxone dispensing. Areas for improvement include addressing stigma and misconceptions around opioids and naloxone use. These remain important targets for improving pharmacy-based naloxone dispensing, although our overall positive results suggest Massachusetts' experience with NSO implementation can inform other states' efforts to expand pharmacy-based naloxone access.
Copyright © 2022 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34511372      PMCID: PMC8742759          DOI: 10.1016/j.japh.2021.08.020

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  37 in total

1.  Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S.

Authors:  Christopher M Jones
Journal:  Int J Drug Policy       Date:  2019-05-03

2.  The changing landscape of naloxone availability in the United States, 2011 - 2017.

Authors:  Patricia R Freeman; Emily R Hankosky; Michelle R Lofwall; Jeffery C Talbert
Journal:  Drug Alcohol Depend       Date:  2018-08-30       Impact factor: 4.492

3.  Operation Naloxone: Overdose prevention service learning for student pharmacists.

Authors:  Lucas G Hill; John Patrick Sanchez; S Andrea Laguado; Kenneth A Lawson
Journal:  Curr Pharm Teach Learn       Date:  2018-07-24

4.  Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.

Authors:  Lucas G Hill; Lindsey J Loera; Kirk E Evoy; Mandy L Renfro; Sorina B Torrez; Claire M Zagorski; Joshua C Perez; Shaun M Jones; Kelly R Reveles
Journal:  Addiction       Date:  2020-11-22       Impact factor: 6.526

Review 5.  Ambiguous identities of drugs and people: A scoping review of opioid-related stigma.

Authors:  Melissa D McCradden; Denitsa Vasileva; Ani Orchanian-Cheff; Daniel Z Buchman
Journal:  Int J Drug Policy       Date:  2019-10-28

6.  Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.

Authors:  Kirk E Evoy; Lindsey Groff; Lucas G Hill; William Godinez; Ravi Gandhi; Kelly R Reveles
Journal:  J Am Pharm Assoc (2003)       Date:  2019-10-25

7.  Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.

Authors:  Alex K Gertner; Marisa Elena Domino; Corey S Davis
Journal:  Drug Alcohol Depend       Date:  2018-06-22       Impact factor: 4.492

8.  Pharmacists' stigma toward patients engaged in opioid misuse: When "social distance" does not mean disease prevention.

Authors:  Amy Werremeyer; Sydney Mosher; Heidi Eukel; Elizabeth Skoy; Jayme Steig; Oliver Frenzel; Mark A Strand
Journal:  Subst Abus       Date:  2021-03-22       Impact factor: 3.716

9.  Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.

Authors:  Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff
Journal:  BMJ       Date:  2013-01-30

Review 10.  Considering the Potential Benefits of Over-the-Counter Naloxone.

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-02-15
View more
  2 in total

1.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

2.  If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.

Authors:  Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Alexander Y Walley; Robin A Pollini
Journal:  BMC Public Health       Date:  2022-04-13       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.